Eupraxia Pharmaceuticals Set to Share Research at UEG Week
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) is excited to announce its participation in the upcoming United European Gastroenterology (UEG) Week 2024. This significant event is renowned among researchers and professionals within the gastroenterology field. It will take place in Vienna, providing a platform for the latest advancements and research presentations.
What to Expect at UEG Week 2024
UEG Week is globally recognized as one of the leading gastroenterology conferences. Here, innovators like Eupraxia will present groundbreaking findings. Eupraxia's poster presentation will focus extensively on the clinical trial results pertaining to its innovative treatment for eosinophilic esophagitis (EoE), a condition that currently lacks effective long-term solutions.
Presentation Details
Eupraxia's poster presentation is categorized under very specialized topics such as oesophageal, gastric, and duodenal disorders. With a poster number PP0584, the presentation titled “Results from Dose Escalation in RESOLVE, an Ongoing Phase 1b/2a Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis,” will be available throughout the hybrid congress, both virtually and onsite.
Research Methodology
The RESOLVE trial, which is currently underway, focuses on exploring various doses of Eupraxia's EP-104GI treatment. By delivering the medication directly into the esophageal wall, the study seeks to validate the effectiveness of this approach for EoE, aiming to provide better outcomes for patients suffering from this challenging condition.
About Eupraxia Pharmaceuticals and Its Innovations
Eupraxia is committed to breaking new ground in biotechnology by developing extended-release products that address significant unmet medical needs. The company utilizes its proprietary DiffuSphere™ technology, which enhances targeted drug delivery. This technology promises to improve therapeutic effects while minimizing adverse events, especially compared to conventional drug delivery techniques.
Future Perspectives
With EP-104GI in Phase 1b/2a studies, Eupraxia is also building a strong pipeline of innovative therapies that may expand into other therapeutic areas beyond gastrointestinal diseases, potentially influencing fields such as oncology and infectious diseases.
Advancing Healthcare Through Innovation
Eupraxia's continuous efforts aim to improve the safety, tolerability, and effectiveness of existing medications while developing new treatment modalities. The insights gained from their clinical trials are invaluable and contribute significantly to the ongoing conversations around treatment options for patients.
Frequently Asked Questions
What is Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative, locally delivered extended-release products.
What is the significance of the UEG Week?
UEG Week is a prominent conference in the gastroenterology field, showcasing the latest research and innovations from around the globe.
What is the focus of Eupraxia's presentation?
The presentation will cover results from the RESOLVE trial regarding the treatment of eosinophilic esophagitis with EP-104GI.
How does DiffuSphere™ technology work?
DiffuSphere™ technology is designed to provide targeted drug delivery with enhanced duration and efficacy while reducing adverse events.
What other areas is Eupraxia exploring?
Eupraxia is exploring various treatment options across multiple therapeutic areas, including oncology and joint inflammatory conditions.